Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Hyperthermia × Capecitabine × Clear all

Phase

Phase 3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 35 Breast Neoplasms 29 Pancreatic Neoplasms 20 Stomach Neoplasms 16 Rectal Neoplasms 16 Neoplasm Metastasis 16 Neoplasms 12 Esophageal Neoplasms 8 Triple Negative Breast Neoplasms 7 Colonic Neoplasms 7 Colorectal Cancer Metastatic 6 Squamous Cell Carcinoma of Head and Neck 4 Carcinoma, Non-Small-Cell Lung 4 Brain Neoplasms 4 Adenocarcinoma 4 Head and Neck Neoplasms 3 Gastrointestinal Neoplasms 3 Biliary Tract Neoplasms 3 Bile Duct Neoplasms 3 Advanced Solid Tumors 3 Sarcoma 2 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Ovarian Neoplasms 2 Melanoma 2 Lymphoma, Non-Hodgkin 2 Liver Neoplasms 2 Diabetes Mellitus, Insulin-Dependent, 12 2 Cholangiocarcinoma 2 Carcinoma, Renal Cell 2 Carcinoma, Hepatocellular 2

Interventions

Diathermy 2 tislelizumab 1 spartalizumab 1 Radiotherapy 1 Oxaliplatin 1 Immune Checkpoint Inhibitors 1 Fluorouracil 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01716949 2017-08-11

HyRec

University of Erlangen-Nürnberg Medical School

Phase 1/2 Unknown

Gastrointestinal

Hyperthermia, Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡